-
DSN From The Blogs: Ideas are your products, too
NEW YORK — Ideas are just as important to a winning company’s overall success as the products and services it sells. So, what’s your company doing to create a culture where the ideas that create your products and services are as important as the products themselves? That’s the question Dan Mack — EVP strategic business development for The Swanson Group and founder of the Mack Elevation Forum — puts to DrugStoreNews.com users in a hot, new content feature that debuted this week on DrugStoreNews.com.
-
Genzyme announces phase-3 results of Lemtrada in patients with relapsing MS
CAMBRIDGE, Mass. — A late-stage clinical trial of a drug under development as a treatment for multiple sclerosis has shown "successful" results.
Genzyme, acquired earlier this year by French drug maker Sanofi, announced results of the phase-3 "CARE-MS II" trial of Lemtrada (alemtuzumab), saying the drug "significantly reduced" worsening of disability and relapse in patients with MS, compared with Rebif (interferon beta-1a), made by Pfizer and German drug maker Merck KGaA, a separate company from U.S.-based Merck.